## ISRG: Intuitive Surgical, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 3.0% below STRENGTH zone (3.0-6.0%); PEG 3.46 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($555.07)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 6, Bearish: 0)

**1. Baird Reaffirms Buy on Intuitive Surgical (ISRG) After New FDA Clearances**
- Source: Insider Monkey | 20251222T150840 | Bullish | Relevance: 100%
- Baird reaffirmed a Buy rating on Intuitive Surgical (ISRG) with a $655 price target, following the FDA's clearance of the da Vinci Single Port (SP) surgical system for three new procedures: inguinal hernia repair, cholecystectomy, and appendectomy. This expands the system's US indications, which already included urology and colorectal surgeries. The da Vinci SP enables complex operations through a single incision, and the company offers various instruments and services supporting these robotic systems globally.

**2. Intuitive Surgical Stock (ISRG) Week Ahead: FDA da Vinci 5 Recall Posting, da Vinci SP Expansion, and Fresh Wall Street Targets Into the Christmas Trading Week**
- Source: ts2.tech | 20251222T002510 | Neutral | Relevance: 100%
- Intuitive Surgical (ISRG) faces a holiday-shortened trading week with key developments: an FDA Class 2 recall on a da Vinci 5 component and expanded FDA clearance for da Vinci SP for three high-volume general surgery procedures. Analysts maintain a "Moderate Buy" consensus with price targets averaging $611.08, while investors will closely watch for any further commentary on the recall and how ISRG trades around its technical levels in a low-liquidity environment.

**3. Truist and RBC Capital Raise Price Targets on Intuitive Surgical (ISRG)**
- Source: Finviz | 20251221T145721 | Bullish | Relevance: 100%
- Truist and RBC Capital have both raised their price targets for Intuitive Surgical (ISRG) to $650, maintaining Buy and Outperform ratings, respectively. This positive outlook is driven by anticipated strong sector fundamentals in MedTech for 2026, supported by aging populations, improved healthcare access, and innovation. Intuitive Surgical's da Vinci 5 system has received positive feedback for its enhanced precision and efficiency.

**4. Intuitive Surgical (ISRG): Reassessing Valuation After Earnings Beat, FDA da Vinci Clearance, and Strategy Shift**
- Source: Simply Wall Street | 20251221T024959 | Bullish | Relevance: 100%
- Intuitive Surgical (ISRG) has seen its stock regain momentum following an earnings beat, FDA clearance for its da Vinci Single Port system, and a strategic shift to direct distribution in Southern Europe. While the company's long-term potential looks strong with ongoing innovation and expansion, its current share price is near all-time highs and trades at a high valuation compared to industry averages. Investors are now questioning if the market is accurately pricing in future growth or if the stock is overvalued, despite a narrative fair value suggesting it is slightly undervalued.

**5. Intuitive Surgical (ISRG) Stock: Latest News, Analyst Forecasts, and 2026 Outlook (Updated Dec. 20, 2025)**
- Source: ts2.tech | 20251221T000818 | Bullish | Relevance: 100%
- Intuitive Surgical (ISRG) is closing out 2025 with strong fundamentals, driven by FDA clearance for its da Vinci SP system's expanded use and bullish analyst targets, with several clustering around $650. Despite a premium valuation and macro uncertainties, the company benefits from significant procedure growth and increasing installed bases for its da Vinci and Ion systems. Investors are keenly watching Q4 2025 earnings in January 2026, da Vinci 5 adoption, and SP utilization for continued momentum.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 2, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-18 | Truist Securiti | $650 | $620 | +5% |
| 2025-12-17 | RBC Capital | $650 | $625 | +4% |
| 2025-12-11 | Citigroup | $635 | $650 | -2% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-18 | Truist Securiti | main | Buy |
| 2025-12-17 | RBC Capital | main | Outperform |
| 2025-12-11 | Citigroup | down | Neutral |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 5 ($2.98M) |
| Sells | 13 ($5.48M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 35.6% |
| Smart Money | **BEARISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 4 |

**Top Holders:**
- Vanguard Group Inc: 9.4% (+0.8%)
- Blackrock Inc.: 8.8% (+0.1%)
- State Street Corpora: 4.3% (-0.1%)
- Price (T.Rowe) Assoc: 3.6% (-4.4%)
- Geode Capital Manage: 2.3% (+1.0%)

### Key Risks

1. Insider selling cluster: $5.5M in recent transactions.
2. Valuation stretched: PEG 3.5x requires aggressive growth execution.
3. Market regime shift could impact high-beta names disproportionately.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Momentum building: MRS_10 improving +2.6% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 3.46 signals overvaluation risk, limited margin of safety. Forward P/E 59.5x stretched relative to 13% growth. Quality metrics strong (margin 29%). Balance sheet: strong liquidity (4.7x), low leverage (D/E 0.14). Institutional flow bearish (4 selling vs 5 buying).

| Metric | Value |
|--------|-------|
| Market Cap | $207.9B |
| Beta | 1.69 |
| 52W Range | $425.00 - $616.00 |
| Short Interest | 2.0% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 3.46 |
| Forward P/E | 59.5 |
| Current P/E | 67.1 |
| YoY Growth | 12.8% |
| EPS Direction | RISING |

### Technicals

MRS_10 strengthening from 0.4% to 3.0% (+2.6% in 5 days), confirming momentum buildup. Below STRENGTH zone by 0.0pp (needs >3.0% for momentum thesis). MRS_5 at 1.2% confirms short-term momentum alignment. Outperforming sector by 3.1pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). OFD pattern: +SUN (Resistance test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 2.99% (CS: 90) | Neutral |
| RSI_14 | 62.5 | Neutral |
| MACD Histogram | -0.50 | Bearish |
| vs SMA20 | 1.026x | Above |
| vs SMA50 | 1.071x | Above |
| vs SMA200 | 1.141x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $579.83
- **Stop Loss:** $555.07 (4.3% risk)
- **Target:** $604.59 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 48
- **Position Value:** $27,831.84
- **Portfolio %:** 27.83%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with improving risk appetite. VIX decline to 52-week lows and moderate breadth recovery suggest calming conditions, though narrow participation indicates selectivity remains key. Positive earnings momentum and AI adoption themes provide fundamental support for quality growth names.*

### Earnings

**Next:** 2026-01-22 (Est: $2.24)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.99 | $2.40 | +20.7% |
| 2025Q2 | $1.92 | $2.19 | +14.1% |
| 2025Q1 | $1.73 | $1.81 | +4.4% |
| 2024Q4 | $1.79 | $2.21 | +23.7% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*